Accelerated Vaccine Introduction AVI

1
Accelerated Vaccine IntroductionAVI
Jon Pearman AVI Product Launch Manager

• Feb 18, 2009
• New York

2
Delayed vaccine introduction in developing
countries
15 years to introduce
3
AVI accelerated vaccine introduction initiative
1 year
for ROTA and PNEUMO Build a platform for future
vaccines
4
Delays of introduction in Europe Prevnar
Gardasil
5
The People
AVI Product Launch Team Matrix structure of key
partners product launch competencies Cross
functional project / development team (line
reporting remains)
J Pearman
C Mantel O Mansoor A Ottosen
J Wecker M Ahun R Eggers
O Levine
Operational Sub-teams report into management team
6
Penta performance
Supply constraints for large birth cohort
countries
Country concerns over long term affordability
Doses mio
Complex application process
Slow acceptance of Hib burden, linked to
difficult surveillance
7
Penta performance
SAGE Global Hib recommendation 2006
Country approvals
Doses mio
Hib initiative set up 2005 with 30m funding
Surge in country approvals for introduction
2008-9
8
Penta understanding the factors influencing
speed of introduction

• Confidence in GAVI, sustainability
• WHO and Hib initiative support for application
  process, SAGE recommendation
• Supply capacity increase - 2nd 3rd and 4th new
  suppliers
• Timing of large country introductions Ethiopia,
  Pakistan, Bangladesh, DRC, India

9
AVI the plan as approved by GAVI board

• Assist countries make decisions on introduction
  of pneumo rota vaccines
• Develop platform for introduction of other new
  vaccines
• Target of 42 pneumo and 44 rota introductions by
  2015
• Detailed work-plan drafted
• partners WHO, UNICEF SD PD, GAVI sec
• AVI TAC Technical Assistance Consortium

Approved Oct 2008
10
AVI TAC selected through a competitive bid
process

• Review committee included
• Dr. Thomas Cherian, WHO
• Dr. Hélène Mambu-Ma-Disu, former WHO
  Representative, Cameroon
• Dr. Deogratias Barakamfitiye, former WHO and MOH
  Burundi
• Ms. Patience Kuruneri, UNICEF
• Dr. Ripley Ballou, Gates Foundation
• Ms. Nina Schwalbe, GAVI Secretariat (Chair)
• Ms. Alyse Forcellina, McKinsey and Company

GAVI Alliance Board meeting 29 30 October 2008
11
Proposals were evaluated based on the following
criteria

• vision and knowledge
• Innovation
• technical expertise
• proposed management and coordination structure
• outcomes and accountability
• cost efficiency
• organizational capacities

12
1 year consultation process resulting work-plan
of 4 area outputs
13
Each area/output has sub-outputs defined (over 20)
14
...and over 100 activities defined
15
Comparison of current strategic demand forecasts
for Pneumo (v2 AMC) and Rota with Penta
(overlay)
Doses m
2 yrs faster
ADIP assumptions for strategic demand, now
responsibility of AVI
16
Thank you
WHO/Christopher Black
17
Main areas for AVI Technical Advisory Consortium
Strategic Vaccine Supply
Advocacy Communication
Special Studies
18
Key milestones in 2009

• EMEA recommends PCV10
• SAGE recommendation on Rotavaccine(s)
• AMC signing industry participation
• WHO QSS approvals
• Submission of proposals for AVI vaccines
• Delivery starts end 2009 Q1 2010

19
AVI funding

• GAVI funding for AVI activities goes to three
  groups

WHO/ UNICEF via Work Plan (SG2)
AVI Outsourced Entity
ADIPs (small number of transitional activities)
Funding requested Oct 2008
Budget endorsed Jun 2008. Funding requested Oct
2008
Previously approved
GAVI Alliance Board meeting 29 30 October 2008
20
Key Components of RFP

• Special studies
• Communication and advocacy
• Strategic vaccine supply
• Support large country introduction
• Support the introduction of future vaccines, as
  they are adopted by GAVI

GAVI Alliance Board meeting 29 30 October 2008
21
Pneumo and Rota are new vaccines
22
Status of Strategic Vaccine Supply

• 2010 price decreases likely
• 6 years for entry of the 2nd penta vaccine

Price US
Doses 000 Supplied offered, UNICEF SD 2007
3 suppliers needed before price decline
Since start of GAVI